UNSPSC 51372025: Etorphine hydrochloride

This classification denotes an opioid receptor agonist with the molecular formula C25H33NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8CBE01N748, chemically known as 6,14-endo-ethenotetrahydrooripavine, 7-alpha-(1-(r)-hydroxy-1-methylbutyl)-, hydrochloride but more generally known as etorphine hydrochloride, which bears US NIH Compound Identifier 61677. Most nations, for tariff and trade purposes, schedule etorphine hydrochloride under HS 29391100 and SITC 54141.

As of Q4 2014, ETORPHINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Etorphine hydrochloride bears US NLM identifiers UMLS ID C0521927 and NCI Concept Code C83705. SMILES: CCC[C@](C)([C@H]1C[C@@]23C=C[C@]1([C@H]4[C@@]25CCN([C@@H]3CC6C5C(C(CC6)O)O4)C)OC)O.CL.

UNSPSC 51372025 Etorphine hydrochloride is a Commodity code that in practice captures state and local procurement of pharmaceutical products and drug-related health-support systems, though recent solicitations tagged under this code show minimal direct activity in etorphine itself and instead reflect broader pharmaceutical supply and opioid-response procurement. State and local issuers soliciting under or near this code span county health departments, state health and human services agencies, and cooperative purchasing alliances. The actual work being bought includes naloxone and drug deactivation systems for community health initiatives, generic multi-source pharmaceuticals and over-the-counter products through authorized wholesaler networks, and market research on direct-to-manufacturer prescription programs. County health departments and state pharmacy benefit programs are the primary buyers; cooperative purchasing vehicles such as the Minnesota Multistate Cooperative Purchasing Alliance amplify reach across multiple states and participating municipalities.

Recent activity concentrates in Florida and Minnesota, with Texas HHS conducting early-stage market research on pharmacy benefit restructuring. Seminole County, Florida issued IFB60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries through July 26, 2023 (response deadline); the procurement includes a two-year initial term with one-year renewal option and requires E-Verify compliance, drug-free workplace certification, and potential FEMA funding compliance. Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued an RFP (S1070000015802) on January 20, 2026 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, with award effective July 1, 2026 and products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) across multiple states including Oregon. Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs, signaling potential future formal procurement once market research concludes.